The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.

Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Danielle Walker, 36, plans to undergo immunotherapy treatment in Germany which costs £35,000 a course :: The family has ...

The study aims to uncover the immunological basis of Tanshi (phlegm-dampness) constitution—a subhealth type in traditional Chinese medicine ...

2025年6月，美国生物技术公司Diakonos Oncology宣布完成200万美元的SAFE（Simple Agreements for Future ...

Men around the world dealing with sexual impotence have been treated for years with the drug sildenafil, sold under brand ...

Scientists have pinpointed a crucial network of immune cells that allows humans to digest food safely without triggering ...

Since the emergence of the Zika virus epidemic in 2014 and the associated novel sequalae that emerged, much has been learned about the effects of antenatal exposure to Zika virus. Zika virus in ...

Harvard Business School (HBS) has named its 2025-26 Blavatnik Fellows and the program’s twelfth cohort. Launched in 2013, the ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...